the development of drugs (Ozempic, the diabetes treatment which has become a popular weight loss drug) that have an application for sleep apnoea, not the research note, is of interest.
. UBS analysts had flagged the rise of weight loss drugs as a potential headwind for the company earlier this year, and have subsequently slashed ResMed’s price target by 36 per cent to $US170, dropping the stock to a “Neutral” rating from a “Buy” rating
The analysts cited the likely regulatory success of Ozempic-like competitor drug SURMOUNT-OSA as a reason for the downgrade.
“The stock no longer looks exceptional on growth versus US peers,” the note said.
SG Hiscock High Conviction Fund buying back in, folloeing the 30 per cent retracement.
. "It’s important to recognise Glucagon Like Peptide (GLP-1) drugs have been around for a while and have not been considered efficacious enough to see commercial take-up and be reimbursed for weight loss. New trials are seeking to show greater clinical benefit from using GLP-1 drugs in reducing the risk of major cardiovascular events and Obstructive sleep apnoea.
"There is still a huge amount of uncertainty around the potential clinical adoption, cost-benefit and commercial take-up of GLP-1 drugs and whether they will allow patients to stop using CPAP machines, and if so, how many.
"The share price reaction for ResMed implies that these drugs will have material uptake and reduce the long-term addressable market for CPAP. This is providing an opportunity to buy a high-quality business at a discount to its longer-term fundamental value."